J&J’s mul­ti­ple myelo­ma ther­a­pies dri­ve on­col­o­gy busi­ness de­spite slow Carvyk­ti sales

John­son & John­son de­fend­ed slow­er-than-ex­pect­ed sales of Carvyk­ti in the first quar­ter, with ex­ecs say­ing they ex­pect sales of the cell ther­a­py to ac­cel­er­ate in the sec­ond half of the year.

The treat­ment brought in $157 mil­lion in sales in the first quar­ter, down from $159 mil­lion in the fourth quar­ter of last year. It had $72 mil­lion in sales in the first quar­ter of 2023.

In an in­vestor call on Tues­day morn­ing, J&J’s world­wide chair­man of in­no­v­a­tive med­i­cine Jen­nifer Taubert said the flat Carvyk­ti sales were due to “phas­ing and tim­ing of or­ders and when they were ac­tu­al­ly de­liv­ered and billed.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER